Blog Single

Executive Summary: Electronic health record and health IT software companies are often valued differently from traditional service businesses because buyers focus less on current earnings alone and more on recurring annual revenue, customer retention, implementation depth, and the difficulty of replacing the platform. Metrics such as annual recurring revenue (ARR), net revenue retention (NRR), deployment stickiness, and switching costs can justify premium valuation multiples when they support durable cash flow, predictable growth, and a strong competitive moat. For Seattle-area founders and owners, especially those tied to the cloud software, digital health, and life sciences ecosystem in South Lake Union, Bellevue, and Redmond, understanding these metrics is essential before a sale, recapitalization, or strategic planning event.

Introduction

Electronic health record (EHR) and health IT software companies occupy a unique place in business valuation. Unlike a conventional product distributor or local service firm, these businesses often rely on subscription revenue, long implementation cycles, and highly embedded workflows inside hospitals, clinics, and specialty practices. That combination can create valuation outcomes that are more aligned with software economics than with traditional healthcare services economics.

For owners, this distinction matters. A buyer evaluating a healthcare software company will usually look beyond reported EBITDA and ask whether the revenue base is recurring, whether clients expand over time, and whether the software is sufficiently integrated into daily operations to make switching painful and expensive. When those answers are favorable, the company may support a meaningfully higher multiple than a business with similar revenue but weaker retention.

At Seattle Business Valuations, we see this dynamic frequently in the Pacific Northwest, where healthcare information technology often overlaps with cloud software, data analytics, and enterprise workflow tools. In a market influenced by Seattle tech corridor capital, Bellevue growth companies, and Redmond software expertise, valuation buyers tend to reward businesses that show durable subscription economics and low customer attrition.

Why This Metric Matters to Investors and Buyers

Recurring revenue is easier to underwrite

ARR is one of the first metrics buyers examine because it captures committed recurring subscription revenue over a 12-month period. In valuation analysis, ARR reduces uncertainty. A company with $10 million of ARR and 90 percent gross retention can often be modeled with more confidence than a business with the same revenue generated through one-time implementations, licensing noise, or project-based support.

In merger and acquisition transactions, recurring revenue often draws higher multiples because it supports forecasting, debt capacity, and exit planning. Buyers can more easily build discounted cash flow (DCF) models when revenue renews predictably. A stable ARR base also tends to support higher EBITDA multiples because recurring revenue lowers perceived risk.

NRR shows whether customers are expanding

Net revenue retention measures how much recurring revenue remains from an existing customer base after churn, downgrades, and expansions are considered. NRR is especially important in EHR and health IT because a company may not only keep customers, but also sell add-on modules, higher service tiers, analytics packages, or interoperable workflow tools.

A company with 100 percent NRR is generally retaining its revenue base. A company with 110 percent or higher NRR is growing within its installed base, which is a strong signal to buyers. In many software transactions, NRR above 110 percent can support premium valuation ranges, while NRR below 90 percent may signal customer dissatisfaction, pricing pressure, or weak product expansion.

Switching costs create a valuation moat

The most valuable health IT platforms are not just used, they are woven into clinical, billing, compliance, and reporting workflows. If replacing the system would require retraining staff, migrating historical records, revalidating integrations, and risking operational disruption, the company has a switching cost moat. That moat is valuable because it decreases churn and increases the likelihood of renewal.

In valuation terms, switching costs improve durability. Durable cash flow often earns a premium because a buyer is less exposed to competitive displacement. In EHR software, the moat is not theoretical. It is often rooted in data migration risk, regulatory complexity, user adoption friction, and the many downstream dependencies that connect the core record system to billing, scheduling, analytics, and population health tools.

Key Valuation Methodology and Calculations

ARR multiples and what drives them

ARR multiples are commonly used to value software companies, especially those with subscription revenue and modest current profitability due to product investment. While the exact range varies by growth rate, customer concentration, product maturity, and margin profile, many buyers and investors think in terms of revenue multiples rather than only EBITDA when the company has clear recurring characteristics.

For lower-growth or more mature health IT businesses, ARR multiples may fall closer to the range associated with stable software assets, often influenced by 3x to 6x recurring revenue, depending on risk and margin quality. Businesses with stronger growth, above-market retention, and clear expansion potential may command meaningfully higher multiples, sometimes in the 6x to 10x range or more in select strategic transactions. The highest outcomes generally require a combination of strong growth, robust margins, and a defensible moat.

These ranges are not formulas, they are valuation signals. A buyer will ask whether the ARR is true recurring revenue, whether implementation fees are nonrecurring, and whether the customer base is concentrated in a small number of health systems or distributed across many accounts. A company with $15 million of ARR derived from many sticky contracts is often more valuable than one with the same ARR but heavy concentration in a handful of accounts.

EBITDA still matters, especially in mature platforms

Even with software-based valuation logic, EBITDA matters. Rules of thumb are common, but the relationship between ARR and EBITDA often reveals the market’s confidence in revenue durability. If a business is growing quickly but investing heavily, buyers may anchor more on ARR multiples. If the platform is mature and producing reliable cash flow, buyers may emphasize EBITDA multiples and cash conversion.

In practice, a healthy EHR and health IT company can trade at a premium to traditional software services because the earning stream is more stable. For example, a company growing 20 percent to 30 percent annually with 110 percent NRR and strong gross margins may support a valuation framework that blends ARR multiples and forward EBITDA. By contrast, a slower-growing business with flat retention may be valued more conservatively, even if current earnings are positive.

Implementation stickiness increases value

Implementation stickiness is the degree to which a platform becomes operationally embedded after deployment. In EHR businesses, that may include workflow customization, third-party integrations, training invested by the customer, and the operational burden of onboarding. The more resources a client has already spent to implement the system, the less likely that client is to rip it out.

Buyers view this stickiness as part of the moat because it stabilizes future revenue. High implementation complexity can also improve valuation when it creates barriers to entry for competitors. However, there is a balance. If implementation is too cumbersome, sales cycles may lengthen and customer satisfaction may weaken. The best outcomes occur when implementation creates long-term lock-in without damaging user experience.

DCF analysis must reflect retention and renewal behavior

A discounted cash flow model can be powerful for health IT valuation, but only if it reflects actual subscription economics. Growth assumptions should be tied to ARR expansion, retention, and customer acquisition efficiency. Discount rates should account for customer concentration, regulatory exposure, reimbursement sensitivity, and sales cycle length.

When NRR is strong and churn is low, projected cash flows become more certain, which can reduce perceived risk and increase value. Conversely, if renewal rates are volatile or implementation revenue is a large portion of gross billings, DCF confidence declines. The same principle applies to precedent transactions, where buyers often pay more for businesses with visible recurring revenue and lower execution risk.

Seattle Market Context

Seattle is a natural home for EHR and health IT valuation conversations because the region combines software talent, cloud infrastructure expertise, and a growing health innovation ecosystem. Companies in South Lake Union, Bellevue, and Redmond often operate at the intersection of software, analytics, and regulated healthcare workflows. That mix tends to produce buyers who are fluent in ARR, retention cohorts, and product-led growth economics.

Regional deal activity also affects valuation expectations. In the Pacific Northwest, strategic buyers often compare health IT assets not only to local peers, but also to cloud software and SaaS transactions across the broader West Coast. A company with strong ARR, durable NRR, and an embedded workflow product may be viewed more favorably in Seattle than in a market where buyers are less familiar with software valuation frameworks.

Washington tax and regulatory considerations should also be part of the analysis. Washington does not impose a state income tax, which can influence owner-level planning and post-sale structuring. At the same time, buyers and sellers must consider Business and Occupation (B&O) tax, sales tax treatment of software and implementation services, and, for some sellers, Washington capital gains tax exposure on higher-value transactions. These issues do not determine enterprise value directly, but they can affect after-tax proceeds and therefore the economics of a deal.

Common Mistakes or Misconceptions

Confusing revenue visibility with profitability

A common mistake is assuming that recurring revenue automatically means high value. It does not. A health IT company can have ARR and still be worth less than expected if customer acquisition is expensive, services margins are weak, or churn undermines revenue quality. Buyers want recurring revenue, but they also want disciplined execution and evidence that the model converts growth into cash.

Overstating switching costs

Some owners overestimate the moat created by implementation complexity. A long implementation alone does not guarantee customer lock-in. If alternative systems offer materially better workflow performance, lower total cost of ownership, or better interoperability, a buyer will discount the supposed moat. Real switching-cost strength is proven by low churn, high renewal rates, and consistent expansion from the installed base.

Ignoring customer concentration

Even high ARR businesses can be risky if a few hospital systems or enterprise accounts account for a disproportionate share of revenue. Concentration can reduce valuation because it creates binary renewal risk. Buyers may still pay a premium for a concentrated platform if the accounts are strategic and deeply embedded, but they will model the downside carefully.

Using the wrong comp set

Health IT companies are sometimes compared to generic medical practices or healthcare services firms, which can produce misleading conclusions. The more relevant comparables often include software and SaaS transactions, especially those involving vertical market software, enterprise workflow tools, or regulated data platforms. Precedent transactions should be selected based on revenue model and retention profile, not just industry label.

Conclusion

EHR and health IT software valuation depends on more than headline revenue or current earnings. Buyers pay close attention to ARR, NRR, implementation stickiness, and the switching cost moat because these metrics tell them whether revenue is truly recurring, whether the customer base is expanding, and whether the platform is difficult to replace. Those factors can justify premium multiples when they are supported by strong operating performance and a coherent growth story.

For Seattle business owners, this analysis is especially relevant in a market shaped by software sophistication, healthcare innovation, and disciplined capital allocation. Whether your company serves clinics, specialty practices, hospital networks, or adjacent healthcare workflows, a valuation should reflect the full quality of the revenue base, not just the latest operating margin.

If you are considering a sale, recapitalization, partner buyout, or strategic planning exercise, Seattle Business Valuations can provide a confidential, well-supported opinion of value tailored to your company’s metrics and market position. Contact us to schedule a private valuation consultation and discuss how ARR, NRR, implementation economics, and switching costs may influence your business value.